Cargando…
Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience
OBJECTIVE: To assess the treatment options and associated complications in patients with May–Thurner’s syndrome (MTS). METHODS: We retrospectively reviewed the charts of patients diagnosed with MTS. Thorough review was completed and data relevant to methods of diagnosis, treatment, complications, ho...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384425/ https://www.ncbi.nlm.nih.gov/pubmed/34447265 http://dx.doi.org/10.2147/IJGM.S325231 |
_version_ | 1783741911832461312 |
---|---|
author | Sigua-Arce, Priscilla Mando, Ramy Spencer, Lisa Halalau, Alexandra |
author_facet | Sigua-Arce, Priscilla Mando, Ramy Spencer, Lisa Halalau, Alexandra |
author_sort | Sigua-Arce, Priscilla |
collection | PubMed |
description | OBJECTIVE: To assess the treatment options and associated complications in patients with May–Thurner’s syndrome (MTS). METHODS: We retrospectively reviewed the charts of patients diagnosed with MTS. Thorough review was completed and data relevant to methods of diagnosis, treatment, complications, hospital readmission, and mortality were extracted from patient charts. The patients were followed for two years after diagnosis. RESULTS: Of the 47 patients identified as having “MTS”, 32 (70%) were diagnosed formally with either magnetic resonance venography, computed tomography venography, or ultrasound. Two patients were excluded for insufficient availability of follow-up records. Mean age of the population included (N = 30) was 50.24 ±15.33 years and 83% (N = 25) had female gender. The majority (40%) of patients were treated with anticoagulation, thrombolysis, and stent placement, and 13.3% received a combination of anticoagulation, antiplatelet agent, thrombolysis, and stent placement. Overall, we found 28 patients (93%) who underwent endovascular stenting. However, 39.3% (11/28) had stent-related complications that included stent thrombosis, stenosis, and migration. One patient underwent open heart surgery for stent retrieval. Duration of anticoagulation therapy ranged from 6 months to lifelong. Two patients (6.7%) suffered major bleeds requiring transfusion. Fourteen patients (46.6%) developed post-thrombotic syndrome. Seven (23.3%) patients required MTS-related readmission within 30 days. No mortality was noted at two-year follow-up. CONCLUSION: Although our study only included 30 patients, it was evident to us that there is no consensus in the management of MTS. Furthermore, endovascular stenting, which has a major role in the management of MTS, has complication rates that hover close to 40%. Further research is needed to help develop a standardized evidence-based approach in the management of MTS that ensures a decreased risk of immediate and long-term complications. |
format | Online Article Text |
id | pubmed-8384425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-83844252021-08-25 Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience Sigua-Arce, Priscilla Mando, Ramy Spencer, Lisa Halalau, Alexandra Int J Gen Med Original Research OBJECTIVE: To assess the treatment options and associated complications in patients with May–Thurner’s syndrome (MTS). METHODS: We retrospectively reviewed the charts of patients diagnosed with MTS. Thorough review was completed and data relevant to methods of diagnosis, treatment, complications, hospital readmission, and mortality were extracted from patient charts. The patients were followed for two years after diagnosis. RESULTS: Of the 47 patients identified as having “MTS”, 32 (70%) were diagnosed formally with either magnetic resonance venography, computed tomography venography, or ultrasound. Two patients were excluded for insufficient availability of follow-up records. Mean age of the population included (N = 30) was 50.24 ±15.33 years and 83% (N = 25) had female gender. The majority (40%) of patients were treated with anticoagulation, thrombolysis, and stent placement, and 13.3% received a combination of anticoagulation, antiplatelet agent, thrombolysis, and stent placement. Overall, we found 28 patients (93%) who underwent endovascular stenting. However, 39.3% (11/28) had stent-related complications that included stent thrombosis, stenosis, and migration. One patient underwent open heart surgery for stent retrieval. Duration of anticoagulation therapy ranged from 6 months to lifelong. Two patients (6.7%) suffered major bleeds requiring transfusion. Fourteen patients (46.6%) developed post-thrombotic syndrome. Seven (23.3%) patients required MTS-related readmission within 30 days. No mortality was noted at two-year follow-up. CONCLUSION: Although our study only included 30 patients, it was evident to us that there is no consensus in the management of MTS. Furthermore, endovascular stenting, which has a major role in the management of MTS, has complication rates that hover close to 40%. Further research is needed to help develop a standardized evidence-based approach in the management of MTS that ensures a decreased risk of immediate and long-term complications. Dove 2021-08-20 /pmc/articles/PMC8384425/ /pubmed/34447265 http://dx.doi.org/10.2147/IJGM.S325231 Text en © 2021 Sigua-Arce et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sigua-Arce, Priscilla Mando, Ramy Spencer, Lisa Halalau, Alexandra Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience |
title | Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience |
title_full | Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience |
title_fullStr | Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience |
title_full_unstemmed | Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience |
title_short | Treatment of May–Thurner’s Syndrome and Associated Complications: A Multicenter Experience |
title_sort | treatment of may–thurner’s syndrome and associated complications: a multicenter experience |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384425/ https://www.ncbi.nlm.nih.gov/pubmed/34447265 http://dx.doi.org/10.2147/IJGM.S325231 |
work_keys_str_mv | AT siguaarcepriscilla treatmentofmaythurnerssyndromeandassociatedcomplicationsamulticenterexperience AT mandoramy treatmentofmaythurnerssyndromeandassociatedcomplicationsamulticenterexperience AT spencerlisa treatmentofmaythurnerssyndromeandassociatedcomplicationsamulticenterexperience AT halalaualexandra treatmentofmaythurnerssyndromeandassociatedcomplicationsamulticenterexperience |